CLOSING THE DIAGNOSTIC GAP IN OVARIAN CANCER DETECTION
With
Associate Professor Michelle Hill
Founder and CEO
ProSeek bio
PEOPLE IN HEALTH CARE SEGMENT
Filmed in Brisbane & Sydney | May 2026
After 15 years in academia, Associate Professor Michelle Hill founded ProSeek bio to address one of the most urgent challenges in women’s health: closing the diagnostic gap in ovarian cancer.
For too long, women suspected of ovarian cancer have faced an impossible choice — undergo invasive surgery for diagnosis, only for up to 80% of those procedures to reveal no cancer, or delay intervention and risk diagnosis at a later stage when treatment options are fewer and survival outcomes are significantly worse.
ProSeek bio is developing a non-invasive blood test designed to help clinicians determine whether surgery is truly necessary. Using advanced glycoproteomics to detect ovarian cancer biomarkers in blood, the technology is being developed to deliver more precise diagnostic insights through blood sample processed in existing pathology laboratories.
The goal is clear: enable earlier diagnosis, reduce unnecessary surgeries, lower healthcare costs and improve survival outcomes for women.
Ovarian cancer remains the most lethal women’s cancer because symptoms are often vague, common and easily overlooked. Bloating, pelvic pain and unexplained weight changes are frequently dismissed, contributing to delayed diagnosis in more than 70% of cases. Yet when ovarian cancer is detected early, more than 90% of women survive at least five years. When diagnosed late, survival drops dramatically.
ProSeek bio was founded to change that reality.
Built on more than a decade of biomarker research, the company is translating academic discovery into a clinical diagnostic tool with the potential to transform how ovarian cancer is detected and managed.
By giving clinicians a faster, safer and less invasive way to assess risk, Assoc Prof Hilll talks about how ProSeek bio is working to change the diagnostic pathway for ovarian cancer — reducing harm, improving decision-making and helping save women’s lives.
Source: Adapted from transcript
Event Credit: Medical Technology Association of Australia (MTAA)
Ovarian cancer statistics credit: Ovarian Cancer Research Foundation (OCRF)
-
Greater flexibility in medicine safety programs delivered by pharmacists
Addressing delegates at PSA26, the Pharmaceutical Society of Australia’s (PSA) yearly conference, the Minister for Health and Ageing, the Hon. Mark Butler MP, announced negotiations are progressing on the First Pharmacy Programs Agreement (1PPA), and that from 1 November, follow-up services for Home Medicines Reviews (HMRs) and Residential Medication Management Reviews (RMMRs) programs will be able to be delivered via telehealth.
-
WA and QLD RSV Immunisation programs show drops in infant hospitalisations
RSV is the number one cause of hospitalisation of Australian children under five years of age, according to the Immunisation Foundation of Australia (IFA). There are mounting concerns that Australians at greatest risk of severe Respiratory Syncytial Virus, or RSV will miss out on protection against the lung infection, with the Federal Government failing to commit to a national RSV immunisation program.
-
More health care volunteers needed for Street Side Medics
Identifying a gap in the healthcare of vulnerable people in New South Wales, Dr Daniel Nour founded Street Side Medics in August 2020, a not-for-profit, GP-led mobile medical service for people experiencing homelessness.
Dr. Daniel Nour is a cardiology advanced trainee at Royal North Shore Hospital and the founder of Street Side Medics, a mobile medical service dedicated to providing GP-led care to individuals experiencing homelessness. The initiative started from a customised van, which serves as a medical clinic, visiting food services and shelters across New South Wales and recently Victoria. Street Side Medics offers free medical care without requiring documentation, ID, or a Medicare card.
